WE CLAIM:

1. A pharmaceutical composition comprising

   tirzepatide, or a pharmaceutically acceptable salt thereof;

   an agent selected from the group consisting of NaCl and propylene glycol; and

   dibasic sodium phosphate.

2. The pharmaceutical composition as claimed by Claim 1, wherein

   the tirzepatide, or a pharmaceutically acceptable salt thereof,

   concentration is from ~~about~~ 5 to ~~about~~ 30 mg/mL.

3. The pharmaceutical composition as claimed by Claim 2

   wherein the dibasic sodium phosphate concentration is from ~~about~~ 1.0 mg/mL to ~~about~~ 3.0 mg/mL.

4. The pharmaceutical composition as claimed by Claim ~~3~~ 2 wherein

   the dibasic sodium phosphate concentration is from ~~about~~ 0.67 mg/mL to ~~about~~ 2.68 mg/mL.

5. The pharmaceutical composition as claimed by Claim 4 wherein the

   dibasic sodium phosphate concentration is ~~about~~ 1.34 mg/mL.

6. The pharmaceutical composition as claimed by Claim 1 wherein the

   tirzepatide, or a pharmaceutically acceptable salt thereof,

   concentration is selected from the group consisting of 5, 10, 15, 20, 25, and

   30 mg/mL.

7. The pharmaceutical composition as claimed by Claim 6 wherein the tirzepatide, or pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 10, 20, and 30 mg/mL.

8. The pharmaceutical composition as claimed by Claim 7

   wherein the agent is NaCl.

9. The pharmaceutical composition as claimed by Claim 8 wherein

   the concentration of NaCl is from ~~about~~ 6.2 mg/mL to ~~about~~ 9.5 mg/mL.

10. The pharmaceutical composition as claimed by Claim 9 wherein the concentration of NaCl is from ~~about~~ 7.0 mg/mL to ~~about~~ 9.0 mg/mL.
11. The pharmaceutical composition as claimed by Claim 10 wherein the NaCl concentration is ~~about~~ 8.2 mg/mL.
12. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from ~~about~~ 5 mg/mL to ~~about~~ 30 mg/mL; dibasic sodium phosphate concentration is from ~~about~~ 0.67 mg/mL to ~~about~~ 2.68 mg/mL; and NaCl concentration is from ~~about~~ 6.2 mg/mL to ~~about~~ 9.5 mg/mL.
13. The pharmaceutical composition as claimed by Claim 12 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from ~~about~~ 5 mg/mL to ~~about~~ 30 mg/mL; dibasic sodium phosphate concentration is ~~about~~ 1.34 mg/mL; and NaCl concentration is ~~about~~ 8.2 mg/mL.
14. The pharmaceutical composition as claimed by Claim 13 wherein the composition is presented in an automatic injection apparatus.
15. The pharmaceutical composition as claimed by Claim 1 wherein the agent is propylene glycol.
16. The pharmaceutical composition as claimed by Claim 15 wherein the concentration of propylene glycol is from ~~about~~ 12.0 mg/mL to ~~about~~ 18.0 mg/mL.
17. The pharmaceutical composition as claimed by Claim 16 wherein the concentration of propylene glycol is from ~~about~~ 14.0 mg/mL to ~~about~~ 16.0 mg/mL.
18. The pharmaceutical composition as claimed by Claim 17 wherein the concentration of propylene glycol is ~~about~~ 15.0 mg/mL.

19. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from ~~about~~ 5 mg/mL to ~~about~~ 30 mg/mL; dibasic sodium phosphate concentration is from ~~about~~ 0.67 mg/mL to ~~about~~ 2.68 mg/mL; and propylene glycol concentration is from ~~about~~ 14.0 mg/mL to ~~about~~ 16.0 mg/mL.
20. The pharmaceutical composition as claimed by Claim 19 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from ~~about~~ 5 mg/mL to ~~about~~ 30 mg/mL; dibasic sodium phosphate concentration is ~~about~~ 1.34 mg/mL; and propylene glycol concentration is ~~about~~ 15.0 mg/mL.
21. The pharmaceutical composition as claimed by Claim 20 wherein the composition is presented in an automatic injection apparatus.
22. The pharmaceutical composition as claimed by Claim ~~21~~ 13 wherein the pH of the composition is from ~~about~~ 6.5 to ~~about~~ 7.5.
23. The pharmaceutical composition as claimed by Claim 22 wherein the pH is from ~~about~~ 6.7 to ~~about~~ 7.3.
24. The pharmaceutical composition as claimed by Claim 23 further comprising one or more preservatives.
25. The pharmaceutical composition as claimed by Claim 24 wherein the composition further comprises a preservative selected from the group consisting of metacresol and phenol.
26. The pharmaceutical composition as claimed by Claim 25 wherein the preservative is metacresol.
27. The~~p~~ pharmaceutical composition as claimed by Claim 26 wherein the metacresol concentration is from ~~about~~ 2.0 mg/mL to ~~about~~ 4.0 mg/mL.
28. The pharmaceutical composition as claimed by Claim 27 wherein the metacresol concentration is ~~about~~ 3.15 mg/mL.
29. The pharmaceutical composition as claimed by Claim 25 wherein the preservative is phenol.

30. The pharmaceutical composition as claimed by Claim 29 wherein the phenol concentration is from ~~about~~ 3.0 mg/mL to ~~about~~ 7.0 mg/mL.
31. The pharmaceutical composition as claimed by Claim 30 wherein the phenol concentration is ~~about~~ 5.0 mg/mL.
32. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or
pharmaceutically acceptable salt thereof, concentration is from ~~about~~ 5 mg/mL to ~~about~~ 30 mg/mL; dibasic sodium phosphate is from ~~about~~ 0.67 to ~~about~~ 2.68 mg/mL; propylene glycol is from ~~about~~ 12.0 mg/mL to ~~about~~ 15.0 mg/mL; and further comprising from ~~about~~ 2.0 mg/mL to ~~about~~ 4.0 mg/mL metacresol.
33. The pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from ~~about~~ 5 mg/mL to ~~about~~ 30 mg/mL; dibasic sodium phosphate is from ~~about~~ 0.67 to ~~about~~ 2.68 mg/mL; propylene glycol is from ~~about~~ 12.0 mg/mL to ~~about~~ 18.0 mg/mL; and further comprising from ~~about~~ 3.0 mg/mL to ~~about~~ 7.0 mg/mL phenol.
34. The pharmaceutical composition as claimed by Claim ~~33~~22 wherein the volume of the composition dose is ~~about~~ 0.5 mL.
35. The pharmaceutical composition as claimed by Claim 34 wherein the composition is to be administered using an automatic injection apparatus.
36. Use of a pharmaceutical composition as claimed by Claim ~~33~~ 22 in the manufacture of a medicament for treating diabetes.
37. The use of Claim 36, wherein the ~~dose~~ composition is to be administered using an automatic injection apparatus.
38. The use of Claim 37, wherein the ~~dose~~ composition is to be administered once weekly.
39. Use of a pharmaceutical composition as claimed by Claim ~~33~~ 22 in the manufacture of a medicament for treating obesity.
40. The use of Claim 39, wherein the composition ~~dose~~ is to be administered

using an automatic injection apparatus.

41. The use of Claim 40, wherein the composition ~~dose~~ is to be administered once weekly.
42. A pharmaceutical composition as claimed by Claim ~~33~~ 22 for use in the treatment of diabetes.
43. A pharmaceutical composition as claimed by Claim ~~33~~ 22 for use in the treatment of obesity.